Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1
and the cell cycle, disruption of DNA damage response pathways, and activation of cell …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but
some cases display an indolent behavior that might not necessitate treatment at diagnosis …

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma of which at least a subset
arises from antigen-experienced B cells. However, what role antigen stimulation plays in its …

Background Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other
small B-cell lymphomas. The clinical and pathological characteristics of patients with this …

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that
generally affects older individuals and continues to have one of the worst outcomes of all the …

To interrogate signaling pathways activated in mantle cell lymphoma (MCL) in vivo, we
contrasted gene expression profiles of 55 tumor samples isolated from blood and lymph …

Cyclin D1− mantle cell lymphomas (MCLs) are not well characterized, in part because of the
difficulties in their recognition. SOX11 has been identified recently as a reliable biomarker of …

Mantle cell lymphoma (MCL) is one of the most aggressive lymphoid neoplasms whose
pathogenesis is not fully understood. The neural transcription factor SOX11 is …